title: Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate.
abstract: Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging coronavirus infecting humans that is associated with acute pneumonia, occasional renal failure, and a high mortality rate and is considered a threat to public health. The construction of a full-length infectious cDNA clone of the MERS-CoV genome in a bacterial artificial chromosome is reported here, providing a reverse genetics system to study the molecular biology of the virus and to develop attenuated viruses as vaccine candidates. Following transfection with the cDNA clone, infectious virus was rescued in both Vero A66 and Huh-7 cells. Recombinant MERS-CoVs (rMERS-CoVs) lacking the accessory genes 3, 4a, 4b, and 5 were successfully rescued from cDNA clones with these genes deleted. The mutant viruses presented growth kinetics similar to those of the wild-type virus, indicating that accessory genes were not essential for MERS-CoV replication in cell cultures. In contrast, an engineered mutant virus lacking the structural E protein (rMERS-CoV-ΔE) was not successfully rescued, since viral infectivity was lost at early passages. Interestingly, the rMERS-CoV-ΔE genome replicated after cDNA clone was transfected into cells. The infectious virus was rescued and propagated in cells expressing the E protein in trans, indicating that this virus was replication competent and propagation defective. Therefore, the rMERS-CoV-ΔE mutant virus is potentially a safe and promising vaccine candidate to prevent MERS-CoV infection.
  
  
  OBJECTIVE
  Since the emergence of MERS-CoV in the Arabian Peninsula during the summer of 2012, it has already spread to 10 different countries, infecting around 94 persons and showing a mortality rate higher than 50%. This article describes the development of the first reverse genetics system for MERS-CoV, based on the construction of an infectious cDNA clone inserted into a bacterial artificial chromosome. Using this system, a collection of rMERS-CoV deletion mutants has been generated. Interestingly, one of the mutants with the E gene deleted was a replication-competent, propagation-defective virus that could only be grown in the laboratory by providing E protein in trans, whereas it would only survive a single virus infection cycle in vivo. This virus constitutes a vaccine candidate that may represent a balance between safety and efficacy for the induction of mucosal immunity, which is needed to prevent MERS-CoV infection.
authors.affiliation: Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Campus Universidad Autónoma de Madrid, Cantoblanco, Madrid, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Almazán
authors.forename: Marta L
authors.initials: ML
authors.lastname: DeDiego
authors.forename: Isabel
authors.initials: I
authors.lastname: Sola
authors.forename: Sonia
authors.initials: S
authors.lastname: Zuñiga
authors.forename: Jose L
authors.initials: JL
authors.lastname: Nieto-Torres
authors.forename: Silvia
authors.initials: S
authors.lastname: Marquez-Jurado
authors.forename: German
authors.initials: G
authors.lastname: Andrés
authors.forename: Luis
authors.initials: L
authors.lastname: Enjuanes
mesh_terms: D002460:Cell Line; D003332:Coronaviridae / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D003333:Coronaviridae Infections / Q000821:virology*; D005818:Genetic Engineering; D006801:Humans; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics* / Q000276:immunology; D014779:Virus Replication
chemical_list: D014764:Viral Proteins; D014765:Viral Vaccines
references.citation: Euro Surveill. 2013 Mar 14;18(11):20427
references.pmid: 23517868
references.citation: Euro Surveill. 2012 Sep 27;17(39):
references.pmid: 23041020
references.citation: J Virol. 2002 Nov;76(22):11518-29
references.pmid: 12388713
references.citation: Emerg Infect Dis. 2013 Mar;19(3):456-9
references.pmid: 23622767
references.citation: J Virol. 2007 Nov;81(21):11620-33
references.pmid: 17715225
references.citation: Euro Surveill. 2013 Jun 13;18(24):
references.pmid: 23787161
references.citation: J Virol. 2003 Apr;77(8):4597-608
references.pmid: 12663766
references.citation: J Virol. 2005 Dec;79(23):14909-22
references.pmid: 16282490
references.citation: Virology. 2010 Mar 30;399(1):120-128
references.pmid: 20110095
references.citation: Lancet Infect Dis. 2013 Sep;13(9):745-51
references.pmid: 23782859
references.citation: Virology. 2002 Apr 25;296(1):177-89
references.pmid: 12036329
references.citation: Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8794-7
references.pmid: 1528894
references.citation: J Virol. 2013 Jul;87(14):7790-2
references.pmid: 23678167
references.citation: Nature. 2013 Aug 8;500(7461):227-31
references.pmid: 23831647
references.citation: Proc Natl Acad Sci U S A. 2000 May 9;97(10):5516-21
references.pmid: 10805807
references.citation: Vaccine. 2006 Jan 30;24(5):652-61
references.pmid: 16214268
references.citation: Vaccine. 2008 Feb 6;26(6):797-808
references.pmid: 18191004
references.citation: N Engl J Med. 2012 Nov 8;367(19):1814-20
references.pmid: 23075143
references.citation: J Virol. 2008 May;82(9):4471-9
references.pmid: 18305050
references.citation: Vaccine. 2005 May 2;23(24):3202-9
references.pmid: 15837221
references.citation: J Virol. 2013 Jun;87(12):6551-9
references.pmid: 23576515
references.citation: Microbes Infect. 2013 Jul-Aug;15(8-9):625-9
references.pmid: 23791956
references.citation: Virology. 2003 Mar 30;308(1):13-22
references.pmid: 12706086
references.citation: Lancet. 2013 Jun 29;381(9885):2265-72
references.pmid: 23727167
references.citation: Immunology. 2007 Dec;122(4):496-502
references.pmid: 17680799
references.citation: J Virol. 2012 Jun;86(11):6258-67
references.pmid: 22438554
references.citation: J Gen Virol. 2013 Aug;94(Pt 8):1749-1760
references.pmid: 23620378
references.citation: Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19944-9
references.pmid: 19036930
references.citation: Nature. 2013 Mar 14;495(7440):251-4
references.pmid: 23486063
references.citation: J Virol. 2007 Feb;81(4):1574-85
references.pmid: 17121802
references.citation: J Virol. 2007 Feb;81(4):1701-13
references.pmid: 17108030
references.citation: J Virol. 2004 Nov;78(22):12683-8
references.pmid: 15507657
references.citation: J Virol. 2013 Jun;87(12):6604-14
references.pmid: 23552422
references.citation: N Engl J Med. 2013 Apr 18;368(16):1560-2
references.pmid: 23550601
references.citation: PLoS Pathog. 2011 Jun;7(6):e1002090
references.pmid: 21695242
references.citation: J Virol. 2007 Jan;81(2):548-57
references.pmid: 17108024
references.citation: J Virol. 2013 Aug;87(16):9379-83
references.pmid: 23785207
references.citation: Arch Virol. 2011 Oct;156(10):1883-90
references.pmid: 21766197
references.citation: mBio. 2012 Nov 20;3(6):
references.pmid: 23170002
references.citation: Nat Rev Microbiol. 2009 Jun;7(6):439-50
references.pmid: 19430490
references.citation: Emerg Infect Dis. 2013 May;19(5):736-42B
references.pmid: 23693015
references.citation: J Virol. 1999 Sep;73(9):7853-9
references.pmid: 10438879
references.citation: MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):480-3
references.pmid: 23760190
references.citation: Sci Rep. 2013;3:1686
references.pmid: 23594967
references.citation: J Gen Virol. 2006 Mar;87(Pt 3):641-650
references.pmid: 16476986
references.citation: Euro Surveill. 2012 Sep 27;17(39):
references.pmid: 23041021
references.citation: J Virol. 2011 Oct;85(19):10058-68
references.pmid: 21752905
references.citation: N Engl J Med. 2013 Aug 1;369(5):407-16
references.pmid: 23782161
references.citation: Vaccine. 2006 Feb 13;24(7):1028-34
references.pmid: 16388880
references.citation: J Virol. 2002 Dec;76(24):12491-502
references.pmid: 12438575
references.citation: J Virol. 2013 May;87(9):5300-4
references.pmid: 23449793
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: J Virol. 2006 Apr;80(7):3670-4
references.pmid: 16537637
references.citation: Nat Med. 2012 Dec;18(12):1820-6
references.pmid: 23142821
references.citation: J Virol. 2013 Sep;87(17):9754-67
references.pmid: 23824792
references.citation: Biotechniques. 1997 Dec;23(6):992-4
references.pmid: 9421622
references.citation: Virology. 2007 Nov 25;368(2):296-308
references.pmid: 17692883
references.citation: Virology. 2008 Jul 5;376(2):379-89
references.pmid: 18452964
references.citation: J Virol. 2008 Aug;82(15):7721-4
references.pmid: 18463152
references.citation: Virus Res. 2008 Apr;133(1):45-62
references.pmid: 17416434
references.citation: J Virol. 2006 Nov;80(21):10900-6
references.pmid: 16928748
references.citation: J Virol. 2010 Aug;84(16):8262-74
references.pmid: 20519394
references.citation: J Virol. 2003 Apr;77(7):4357-69
references.pmid: 12634392